Related Experiment Video
Updated: Jul 7, 2026

Screening Assays to Characterize Novel Endothelial Regulators Involved in the Inflammatory Response
Published on: September 15, 2017
[Regulation of proinflammatory cytokine cascade in Kawasaki disease]
Susumu Furukawa1, Tomoyo Matsubara, Takashi Ichiyama
1Department of Pediatrics, Yamaguchi University Graduate School of Medicine.
Insights
Kawasaki disease involves systemic inflammation driven by cytokines like TNF-alpha. This study examines how IVIG, corticosteroids, and anti-TNF agents combat inflammation in Kawasaki disease.
Area of Science:
- Immunology
- Cytokine biology
- Vascular inflammation
Context:
- Kawasaki disease (KD) is a critical pediatric illness characterized by systemic inflammation and vascular injury.
- Tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine, significantly contributes to vascular damage in KD.
- Nuclear factor kappa B (NF-kappaB) activation in monocytes/macrophages is implicated in KD pathogenesis.
Purpose:
- To elucidate the distinct anti-inflammatory mechanisms of Intravenous Immunoglobulin (IVIG), corticosteroids, and anti-TNF agents in Kawasaki disease.
- To compare the therapeutic actions of standard and novel treatments for KD.
Summary:
- Kawasaki disease (KD) is a cytokine-associated systemic inflammatory response syndrome.
- NF-kappaB activation in peripheral blood monocytes/macrophages is central to KD's vascular injury.
- Standard KD therapy includes IVIG and corticosteroids; emerging biologic therapies target TNF-alpha.
Impact:
- Understanding these varied mechanisms can optimize treatment strategies for KD patients.
- This research aids in developing more effective therapies for refractory KD cases.
- Provides insights into managing cytokine-driven inflammatory diseases.
Abstract:
Kawasaki disease (KD) is one of the cytokine-associated diseases, which is systemic inflammatory response syndrome. Tumor necrosis factor-alpha(TNF-alpha), as proinflammatory cytokine, plays an important role in the vascular injury of KD. Nuclear factor kappa B (NF-kappaB) is a pivotal transcription factor for genes that encode the proinflammatory cytokines, chemokines and adhesion molecules that mediate inflammation. We have already reported the activation of NF-kappaB in peripheral blood mononuclear cells with the dominant of monocytes/macrophages. There is ample evidence of a central role of peripheral blood monocytes/macrophages during acute KD. The standard therapy of KD is intravenous immunoglobulin (IVIG). According to circumstances, corticosteroid has been used to treat the KD patients. Recently, it has been reported that new biologic therapy, such as anti-TNF agents are useful for the patients who failed to respond to an initial IVIG. We focus on the different mechanism of IVIG, corticosteroid and anti-TNF agents with regard to the anti-inflammatory effects.
Related Concept Videos
Inflammatory Response
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
The JAK-STAT Signaling Pathway
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Inflammatory Bowel Disease III: Crohn's Disease
T Cell Types and Functions
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Acute Inflammation III: Local and Systemic Effects